Cargando…

Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?

Detalles Bibliográficos
Autores principales:	Tokumaru, Yoshihisa, Le, Lan, Asaoka, Mariko, Futamura, Manabu, Ishikawa, Takashi, Yoshida, Kazuhiro, Takabe, Kazuaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580860/ https://www.ncbi.nlm.nih.gov/pubmed/33102162 http://dx.doi.org/10.21037/tcr-20-2231

Ejemplares similares

High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Organoids Are Limited in Modeling the Colon Adenoma–Carcinoma Sequence
por: Tokumaru, Yoshihisa, et al.
Publicado: (2021)

NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation
por: Wu, Rongrong, et al.
Publicado: (2022)

Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

High Expression of miR-34a Associated with Less Aggressive Cancer Biology but Not with Survival in Breast Cancer
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

Intratumoral Adipocyte-High Breast Cancer Enrich for Metastatic and Inflammation-Related Pathways but Associated with Less Cancer Cell Proliferation
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer
por: Tokumaru, Yoshihisa, et al.
Publicado: (2021)

Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future
por: Asaoka, Mariko, et al.
Publicado: (2020)

DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells
por: Tajirika, Toshihiro, et al.
Publicado: (2018)

APOBEC3-Mediated RNA Editing in Breast Cancer is Associated with Heightened Immune Activity and Improved Survival
por: Asaoka, Mariko, et al.
Publicado: (2019)

Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment
por: Takeshita, Takashi, et al.
Publicado: (2022)

Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase
por: Tokumaru, Yoshihisa, et al.
Publicado: (2019)

Breast reconstruction using a tissue expander after enucleation of a giant fibroadenoma: A case report
por: Kitazawa, Mai, et al.
Publicado: (2021)

Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

The mode of progressive disease affects the prognosis of patients with metastatic breast cancer
por: Mori, Ryutaro, et al.
Publicado: (2018)

Appendicitis caused by the metastasis of HER2-positive breast cancer
por: Mori, Ryutaro, et al.
Publicado: (2016)

G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor
por: Takeshita, Takashi, et al.
Publicado: (2019)

Commentary: Pleurography: We can, but should we?
por: Benz, Cecilia, et al.
Publicado: (2021)

Glucose transporter-1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells
por: Shima, Takafumi, et al.
Publicado: (2022)

Should we modulate the neonatal microbiome and what should be the goal?
por: van Best, Niels, et al.
Publicado: (2022)

Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer
por: Oshi, Masanori, et al.
Publicado: (2022)

Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate
por: Takahashi, Hideo, et al.
Publicado: (2020)

The Role of the Microbiome on the Pathogenesis and Treatment of Colorectal Cancer
por: Yu, Irene, et al.
Publicado: (2022)

Should we breathe quiet or noisy?
por: Putensen, Christian, et al.
Publicado: (2014)

Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival
por: Okano, Maiko, et al.
Publicado: (2019)

Noninvasive ventilation for acute lung injury: how often should we try, how often should we fail?
por: Garpestad, Erik, et al.
Publicado: (2006)

Understanding environmental influences on nutrition and physical activity behaviors: where should we look and what should we count?
por: Ball, Kylie, et al.
Publicado: (2006)

Breast cancer research: where we are and where we should go
por: Liu, Edison T
Publicado: (2000)

Should we go nuts about nuts?
por: Rohrmann, Sabine, et al.
Publicado: (2013)

How should we address the pipeline problem?
por: Braun, Hillary J.
Publicado: (2016)

Zika virus in the testes: should we be worried?
por: Wong, Gary, et al.
Publicado: (2017)

Vaccine safety concerns: Should we be changing the way we support immunization?
por: MacDonald, Noni E, et al.
Publicado: (2020)

Commentary: Just because we can, doesn't always mean we should
por: Nellis, Joseph R., et al.
Publicado: (2021)

What Should We Recommend for Colorectal Cancer Screening in Adults Aged 75 and Older?
por: Arora, Anuj, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tv95jci6qarvgssg121cskiqh7